The Pharmacy of the Specialized Component of Pharmaceutical Policy of the 9th Regional Health Department of the State of Paraná and the Treatment of Ankylosing Spondylitis
Document title: The Pharmacy of the Specialized Component of Pharmaceutical Policy of the 9th Regional Health Department of the State of Paraná and the Treatment of Ankylosing Spondylitis
Journal: Brazilian Journal of Pharmaceutical Sciences
Database: PERIÓDICA
System number: 000452100
ISSN: 1984-8250
Authors: 1
2
1
Institutions: 1Universidade Estadual de Maringa, Programa de Pos-graduacao em Assistencia Farmaceutica, Maringa, Parana. Brasil
2Universidade Estadual de Maringa, Departamento de Estatistica, Maringa, Parana. Brasil
Year:
Volumen: 58
Country: Brasil
Language: Inglés
Document type: Artículo
Approach: Analítico, descriptivo
English abstract The objective of this study was to trace the profile of patients with Ankylosing Spondylitis treated at the Pharmacy of the 9th Regional Health Department of Paraná and evaluate the relationship between pharmacological treatment, quality of life and disease activity index of these patients. Data collection was performed through interviews, application of BASDAI index and the ASQoL questionnaire. Male patients presented better rates (ASQoL 7.78 ± 6.04, BASDAI 4.26 ± 2.40) than female patients (ASQoL 12.08 ± 4.74, BASDAI 6.25 ± 2.43; p <0.05). Retired patients had higher disease activity and lower quality of life (BASDAI 6.59 ± 1.53, ASQoL 14 ± 2.89) than those who still worked (BASDAI 4.59 ± 2.87, ASQoL 7.68 ± 5.74); p <0.05), and the quality of life of patients with comorbidity (ASQoL 11.60 ± 5.47) was lower when compared to those without comorbidity (ASQoL 6.83 ± 4.90, p <0.05). Patients who used immunobiological drugs had better results (ASQoL 9.07 ± 5.86, BASDAI 4.73 ± 2.55) than those who used other drugs (ASQoL 13.08 ± 3.7, BASDAI 6.88 ± 2.15, p <0.05), and patients who used adalimumab showed better rates (ASQoL 7.42 ± 4.81, BASDAI 4.26 ± 2.47; p <0.05) when compared to other pharmacological treatments. Male patients showed a better response when compared to the female counterparts. Patients using adalimumab had a better quality of life and disease activity index than patients using other pharmacological treatments
Disciplines: Medicina
Keyword: Reumatología,
Farmacología,
Salud pública,
Espondilitis anquilosante,
Servicios farmacéuticos
Keyword: Rheumatology,
Pharmacology,
Public health,
Ankylosing spondylitis,
Pharmaceutical services
Full text: Texto completo (Ver HTML) Texto completo (Ver PDF)